Dynamic changes in specific anti-L-asparaginase antibodies generation during acute lymphoblastic leukemia treatment.

Journal: Pharmacological reports : PR
PMID: 30826572

Abstract

BACKGROUND: L-asparaginase (L-asp) remains one of the key components of acute lymphoblastic leukemia therapy. Immune reactions to the drug are associated with its diminished activity. The aim of the study was to determine the level of IgM, IgG and IgE-class anti-L-asp antibodies during the induction and reinduction phases of acute lymphoblastic leukemia therapy and their influence on L-asp activity.

Authors

  • Justyna Walenciak
    Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Łódź, Poland.
  • Krystyna Wyka
    Laboratory of Immunopathology and Genetics, Medical University of Lodz, Łódź, Poland.
  • Szymon Janczar
    Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Łódź, Poland.
  • Wojciech Młynarski
    Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Łódź, Poland.
  • Beata Zalewska-Szewczyk
    Department of Pediatrics, Oncology, Hematology and Diabetology, Medical University of Lodz, Łódź, Poland. Electronic address: beata.zalewska-szewczyk@umed.lodz.pl.

Keywords

External Resources

Popular Topics
Recent Journals